Nicholette Conway is an experienced and independent healthcare leader with over 25 years of experience across the pharmaceuticals, medical devices, and diagnostics sectors. Her work is driven by a deep commitment to improving patient access to innovative treatments. Throughout her career, she has collaborated with precision medicine and health tech startups, biotech and medtech scale-ups, and held senior positions roles in major pharmaceutical companies including Eli Lilly, Amgen, MSD, and Bayer. With a pragmatic and forward-thinking approach, Nicholette combines strategic vision with deep stakeholder engagement—particularly championing the role of patient advocacy groups in shaping care pathways. As the current Board Chair of Genetic Alliance Australia, she plays a key role in advancing access to precision medicine and emerging health technologies. Her work spans commercialization, education, and workforce development, with a strong entrepreneurial mindset that bridges innovation and impact across the healthcare ecosystem.